Searchable abstracts of presentations at key conferences in endocrinology

ea0059pl8 | Society for Endocrinology Dale Medal Lecture | SFEBES2018

Disorders of Thyroid Hormone Action: insights into biological processes

Chatterjee Krishna

Disorders of thyroid hormone action are classified broadly, to encompass conditions with defective cellular uptake, metabolism or nuclear action of thyroid hormones. We describe recent insights into two rare disorders of thyroid hormone action. Impaired conversion of T4 to T3 enables recognition of a multisystem disorder due to mutations in SECISBP2 – a factor directing synthesis of 25 different human, selenocysteine-containing proteins that...

ea0037s4.2 | Thyroid hormone and cardiovascular system | ECE2015

Cardiovascular impact of thyroid hormone receptor mutations

Chatterjee Krishna

The actions of thyroid hormones (TH) are mediated by receptors (TRα1, TRβ1, TRβ2), encoded by separate genes (THRA, THRB), with differing tissue distribution. TRβ2 mediates negative feedback within the hypothalamic-pituitary axis, with TRβ1 being expressed in the liver & kidney; TRα1 predominates in the myocardium and skeletal muscle.Resistance to Thyroid Hormone, usually due to heterozygous TRβ mutations (...

ea0034pl6 | BTA Pitt-Rivers lecture | SFEBES2014

Disorders of thyroid hormone action: insights from human genetics

Chatterjee Krishna

Disorders of thyroid hormone action are classified broadly, to encompass conditions with defective cellular uptake, metabolism or nuclear action of thyroid hormones. Mutations in SECISBP2 cause a multisystem disorder of defective selenoprotein synthesis, with features due to tissue-specific selenoprotein deficiencies (e.g. male infertility, muscular dystrophy), raised cellular reactive oxygen species due to lack of antioxidant selenoenzymes (e.g. photosensitivity, increased ad...

ea0044ep75 | (1) | SFEBES2016

The challenges to diagnose and differentiate TSHoma from thyroid hormone resistance: a case report

Hamdan Khaliq , Koulouri Olympia , Gurnell Mark , Chatterjee Krishna , Owen Penelope

TSHoma is rare, with an incidence of 1 per million, and <1% of all pituitary tumours. We reported a case involving a 49-year-old female who was first referred to our endocrine unit in 2006 with excessive lethargy and abnormal TFT’s. She was thought to have thyroid hormone resistance for several years until 2015 when she reported having persistent symptoms and further investigation suggested an alternative diagnosis.Results: Ft4=41.6 pmol/l, TSH=...

ea0028p367 | Thyroid | SFEBES2012

Fixed drug eruption in the endocrine clinic: rare presentation of reaction to carbimazole

Pan Shwe Zin Chit , Wood Diana , Chatterjee Krishna

Background: Antithyroid drugs include thioimidazoles (carbimazole, methimazole) and propylthiouracil. Carbimazole is most commonly used in the UK. A fixed drug eruption is the drug-induced cutaneous reaction which occurs at the same site after each exposure to that agent. It is uncommon with anti-thyroid medications. Here we report this rare presentation. A 40-year-old Chinese lady who was diagnosed with Graves’ disease was initially treated with carbimazole, and then wit...

ea0050p251 | Neoplasia, Cancer and Late Effects | SFEBES2017

Endocrinopathies are a frequent Consequence of Immune Checkpoint Inhibitor Therapy, with a Low Recovery Rate of both Thyroid and Pituitary Dysfunction

McGowan Anne , Weatherby Tom , Powlson Andrew , Parkinson Christine , Chatterjee Krishna , Corrie Pippa , Moran Carla

Background: Immune checkpoint (CTLA-4, PD-1) inhibitors are increasingly used to treat cancers including advanced melanoma. Although endocrine immune related adverse events (IRAEs) are now well reported, the frequency and type of thyroid and pituitary dysfunction reported varies considerably, with hypophysitis after CTLA-4 inhibitors reported in 2–16%, and thyroid dysfunction after PD-1 inhibitors in 2–39%. In addition, recove...

ea0050p251 | Neoplasia, Cancer and Late Effects | SFEBES2017

Endocrinopathies are a frequent Consequence of Immune Checkpoint Inhibitor Therapy, with a Low Recovery Rate of both Thyroid and Pituitary Dysfunction

McGowan Anne , Weatherby Tom , Powlson Andrew , Parkinson Christine , Chatterjee Krishna , Corrie Pippa , Moran Carla

Background: Immune checkpoint (CTLA-4, PD-1) inhibitors are increasingly used to treat cancers including advanced melanoma. Although endocrine immune related adverse events (IRAEs) are now well reported, the frequency and type of thyroid and pituitary dysfunction reported varies considerably, with hypophysitis after CTLA-4 inhibitors reported in 2–16%, and thyroid dysfunction after PD-1 inhibitors in 2–39%. In addition, recove...

ea0069oc10 | Oral Communications | SFENCC2020

Hiding in plain sight: A case of severe refractory primary hyperparathyroidism due to an intrathyroidal ectopic parathyroid adenoma

Glasgow John C , Chatterjee Krishna , Fish Brian , Berman Lol , Marker Alison , Moran Carla , Casey Ruth

Section 1: Case history: A 30 year-old female patient with a background of symptomatic primary hyperparathyroidism diagnosed in 2008 and a history of two failed neck surgeries, was reviewed in clinic complaining of persistent symptoms of hypercalcaemia. Previous pre-operative neck imaging had failed to localise a parathyroid adenoma and the patient had undergone two neck explorations by an experienced ENT surgeon; one which removed thymic tissue and the other which removed a m...

ea0065p403 | Thyroid | SFEBES2019

Iopanoic acid safely, quickly and effectively induces euthyroidism in resistant thyrotoxicosis

Samudrala Havish , Terry Isabelle , Wong Kah Fai , Wood Diana , Chatterjee Krishna , Moran Carla

Introduction: Thyrotoxicosis resistant to the usual treatment is rare, but potentially fatal. In such situations, the optimal next treatment is unclear. Iopanoic acid (IA) was historically used as an oral contrast agent; it’s capacity to treat thyrotoxicosis has been limited in recent years due to its restricted availability.Methods: Retrospective case note review of patients treated with IA for resistant thyrotoxicosis at our institution over the p...

ea0048o3 | Oral Communications | SFEEU2017

Compensated hyperthyrotropinaemia due to partial loss-of-function mutation in TSH receptor gene

McGowan Anne , Moran Carla , Vanderpump Mark , Dattani Mehul , Chatterjee Krishna , Schoenmakers Nadia

Case history: A clinically euthyroid 7-year-old boy was noted to have a persistently elevated TSH 7.35–14 mU/l (NR 0.27–4.2) and normal FT4 15.0 pmol/l (NR 10-24) with negative anti-thyroid peroxidase antibodies. Thyroid ultrasonography revealed a eutopically-located thyroid gland of normal size. Following commencement of levothyroxine, he developed insomnia, irritability and headaches, resulting in cessation of treatment. Growth and development proceeded ...